Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region

• Váldodahkkit: Zoltán Kaló (Dahkki), Zoltán Vokó (Dahkki), Andrew Östör (Dahkki), Emma Clifton-Brown (Dahkki), Radu Vasilescu (Dahkki), Alysia Battersby (Dahkki), Edward Gibson (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Taylor & Francis Group, 2017-01-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Background & Objectives: Biological disease-modifying antirheumatic drugs (bDMARDs) for the treatment of rheumatoid arthritis (RA) are not always accessible to all patients in accordance with international guidelines, partly owing to their high direct costs against a background of restricted hea...